2019
DOI: 10.2174/1381612825666190716141851
|View full text |Cite
|
Sign up to set email alerts
|

Recent Progress of Adenosine Receptor Modulators in the Development of Anticancer Chemotherapeutic Agents

Abstract: Increased risks of peripheral toxicity and undesired adverse effects associated with chemotherapeutic agents are the major medical hurdles in cancer treatment that worsen the quality of life of cancer patients. Although several novel and target-specific anticancer agents have been discovered in the recent past, none of them have proved to be effective in the management of metastatic tumor. Therefore, there is a continuous effort for the discovery of safer and effective cancer chemotherapeutic agent. Adenosine … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 133 publications
0
8
0
Order By: Relevance
“…These promising results suggest that this compound could also be used on patients with other diseases, such as liver cirrhosis or inflammation [91]. Cl-IB-MECA is able to inhibit lung metastases formation in mice with melanoma at a nanomolar concentration range [27]. In addition, Cl-IB-MECA shows a synergistic antitumor effect when employed in combination with cyclophosphamide [27].…”
Section: A 3 Ar Agonists and Antagonists In Cancer Treatment General Overviewmentioning
confidence: 99%
See 2 more Smart Citations
“…These promising results suggest that this compound could also be used on patients with other diseases, such as liver cirrhosis or inflammation [91]. Cl-IB-MECA is able to inhibit lung metastases formation in mice with melanoma at a nanomolar concentration range [27]. In addition, Cl-IB-MECA shows a synergistic antitumor effect when employed in combination with cyclophosphamide [27].…”
Section: A 3 Ar Agonists and Antagonists In Cancer Treatment General Overviewmentioning
confidence: 99%
“…2). Based on this evidence, A 3 AR is gaining interest for its potential use as a therapeutic antitumor target [15,27]. It is thus clear that adenosine and A 3 AR, play a fundamental role in cancer.The aim of this review is to discuss the characteristics of A3AR and its cancer-related activities.…”
Section: Adenosine Receptorsmentioning
confidence: 99%
See 1 more Smart Citation
“…The A 2A R is overexpressed in some cancers, such as head and neck squamous cell carcinoma, lung, melanoma, and in several breast cancer cells lines, and has been shown to induce PLC, PKC, AKT, MAPK/ERK, and JNK signaling pathways to promote cell proliferation in vitro via inhibition of natural killer cells cytotoxicity, T‐cell activity, and tumor‐specific CD4+/CD8+ activity (Gorainet al, 2019; Marwein et al., 2019). Escaping immune destruction is one of the hallmarks of cancer and overcoming suppressive mechanisms in the tumor niche is a major focus for enhancing immunotherapies.…”
Section: Compounds With Identified Molecular Targetsmentioning
confidence: 99%
“…Although all four ARs are reported to be involved in cancer progression [16,29,30,31], the other three ARs have been shown both to be pro- and anti-tumoral [16]. For example, both pro- and anti-tumoral effects have been reported for the A 1 AR [16].…”
Section: Introductionmentioning
confidence: 99%